Contraceptive Technology Update – January 1, 2006
January 1, 2006
View Issues
FDA revises Evra safety labeling due to increased estrogen levels
Get ready to discuss questions about the safety of the Evra contraceptive patch (Ortho-McNeil Pharmaceutical, Raritan, NJ) now that the Food and Drug Administration (FDA) has revised the transdermal contraceptives labeling.Continuous regimen OCs: Will U.S. see new pill?
Many of your patients may now be using the extended regimen oral contraceptive (OC) Seasonale (Barr Labs, Pomona, NY), where an active pill is taken for 84 days, followed by seven days of placebo pills. But what if there was a pill that would offer continuous dosing with no pill-free intervals?Microbicide development gets a corporate boost
The long road toward a woman-controlled form of prevention against HIV infection may have just gotten a little shorter with the recent agreement by two major drug companies to license promising compounds at no charge for microbicide development to a nonprofit group.Barr set to acquire IUD manufacturer
Intrauterine contraception may see a wider audience in the United States with a major pharmaceutical companys acquisition of the manufacturer of the ParaGard TCu 380A intrauterine device (IUD).Task force issues new gonorrhea guidelines
When you scan your next chart, it gives the medical history of a 19-year-old woman who has been sexually active with multiple partners and inconsistently uses condoms. She reports a painful or burning sensation when urinating and increased vaginal discharge. What is your next move?Progestin-only pills: Where do they fit in?
Your next patient is a young mother who just gave birth to a healthy infant eight weeks ago. She is breast-feeding her baby and wants to use a safe method of contraception that will not affect her milk supply. What option will she choose?Raise the antenna on ovarian cancer
The woman sitting in front of you tells you that she has been experiencing abdominal pain, abdominal swelling, gastrointestinal symptoms, and pelvic pain. What is your next move?STD Quarterly: HPV vaccine on the horizon — Will it be added to immunization schedules?
When you review immunization schedules with your adolescent patients this year, will a vaccine for human papillomavirus (HPV) be added to your discussion list? While no vaccine has yet been approved, recent scientific advances signal that such a vaccine soon may become a reality.STD Quarterly: Raise the radar on chlamydia screening
In reviewing patient files from the last month, how many chlamydia tests were performed at your facility, and how many yielded positive results? If your clinic is seeing an increase in screens, as well as a higher incidence of infection, you are part of a larger nationwide trend.STD Quarterly: Register for 2006 STD prevention conference
The 2006 STD Prevention Conference, Beyond The Hidden Epidemic: Evolution or Revolution? will be held May 8-11, 2006, at the Hyatt Regency Jacksonville (FL) Riverfront.